Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14812141 | 0.96 | CA1 (0.62) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11302478 | 0.95 | CA12 (0.57) | CA12CA1CA2CA9LMNA | |
| SCHEMBL926118 | 0.88 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL21430480 | 0.87 | CA1 (0.59) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL21429187 | 0.86 | CA12 (0.64) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL18295353 | 0.86 | CA1 (0.64) | CA12CA1CA2CA9LMNA | |
| SCHEMBL17974334 | 0.85 | CA12 (0.66) | CA12CA1CA2CA9LMNA | |
| SCHEMBL17974332 | 0.85 | CA12 (0.66) | CA12CA1CA2CA9LMNA | |
| SCHEMBL21601467 | 0.85 | CA12 (0.69) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL928154 | 0.85 | CA12 (0.59) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2019243576-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | GUBRA APS (DK) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243576-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | GUBRA APS (DK) | 2019-12-26 | — | — | WO | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2665829-A1 | COMPOUNDS AND METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF HDAC INTERACTING COMPOUNDS | Cellzome GmbH (DE) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012098006-A1 | COMPOUNDS AND METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF HDAC INTERACTING COMPOUNDS | CELLZOME AG (DE) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011574-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | CA12 1566/4885CA1 1417/4885CA2 1135/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | CA12 1369/4885CA1 1260/4885CA2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.